Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

NCT04134182 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Kidney Cancer Research Bureau